We found that isorhamnetin treatment of NASH-induced mice could attenuate DNL pathway by regulating lipogenic key transcription factor, SREBP1c, which, in turn, downregulated lipogenic enzymes. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatohepatitis.